证券日报网讯2月2日，吉贝尔在互动平台回答投资者提问时表示，截至2026年1月30日收市，公司股东 总数为7919户。 ...

一座电站，句容抽水蓄能电站，上水库大坝高达182.3米，是全球坝体最高的抽水蓄能电站。 一家企业，天奈科技，专注研发生产纳米级碳材料，是全球最大的碳纳米管与碳纳米管浆料生产企业。 一台设备，慧创医疗NirSmart，是全球最早获得NMPA注册证的便携式近红外脑功能成像装置。 这些"全球之最"的创造者，不是北上广深一线城市，也不是杭宁苏蓉二线城市，而是在江苏省"最小"的地级市——镇江。 极强的反差感背后，是一座中小城市的产业突围之路。 小体量，也能迸发高能量！ 01 "最小"与"最强" 在江苏"十三太保"中，镇江的面积是最小的。 3840平方公里，仅为徐州的四分之一，连云港的二分之一。 土地是人类生存的根基，数量、质量与空间分布构成了人口容量的刚性边界。 土地面积小，意味着无法容纳太多的常住人口。 事实也正是如此，数据显示，镇江常住人口322.6万，仅为南京的三分之一，盐城的二分之一，排名全省倒数第一。 无论是土地视角，还是人口维度，镇江都称得上是江苏"最小"的城市。 土地是财富之母，劳动是财富之父。 土地小，人口少，这几乎决定了镇江的经济体量的上限。 出人意料的是，镇江的GDP并非倒数第一，而是排在了面积更大 ...

证券日报网讯1月29日，吉贝尔在互动平台回答投资者提问时表示，公司及管理层关注二级市场股票价 格，高度重视股东利益，专注主营业务发展，提升公司核心竞争力，促进公司高质量发展，持续创造价 值，回报股东，回馈社会。 ...

（文章来源：证券日报） 证券日报网讯 1月22日，吉贝尔在互动平台回答投资者提问时表示，公司将持续专注主营业务发展，通 过产品推广、研发创新、投资布局、股权激励、完善研发技术平台等多种措施，持续促进公司高质量发 展。 ...

证券日报网讯 1月22日，吉贝尔在互动平台回答投资者提问时表示，截至2026年1月20日收市，公司股 东总数为7894户。公司股东情况敬请关注公司披露的定期报告。 （文章来源：证券日报） ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：公司现有产品生命周期怎么样？是否有新的管线研发 保证公司长远稳步发展？ 吉贝尔（688566.SH）1月22日在投资者互动平台表示，公司产品种类丰富，产品功能覆盖多个治疗领 域，主要产品利可君片在口服升白化药领域，尼群洛尔片在高血压伴高心率细分领域具有良好的应用前 景；同时，公司构建了以复方制剂研发技术、氘代药物研发技术、脂质体药物研发技术为支撑的研发技 术平台，正在开展抗抑郁新药JJH201501、抗肿瘤新药JJH201601等创新型药物的研发工作，持续丰富产 品体系。 ...

Core Viewpoint - The stock of Jibeier has experienced fluctuations, with a recent decline of 2.00% and a total market value of 5.863 billion yuan, reflecting mixed investor sentiment and trading activity [1]. Group 1: Stock Performance - As of January 15, Jibeier's stock price is 29.40 yuan per share, with a trading volume of 39.944 million yuan and a turnover rate of 0.67% [1]. - Year-to-date, the stock has decreased by 1.51%, with a 3.29% drop over the last five trading days, a 4.11% increase over the last 20 days, and a 9.48% decline over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jibeier reported a revenue of 704 million yuan, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million yuan, up by 12.80% [2]. Group 3: Shareholder Information - As of January 9, 2025, Jibeier has 7,406 shareholders, an increase of 3.35% from the previous period, with an average of 26,928 circulating shares per shareholder, a decrease of 3.24% [2]. - Since its A-share listing, Jibeier has distributed a total of 476 million yuan in dividends, with 252 million yuan distributed over the last three years [3]. - Notable new institutional shareholders include Caitong Advantage Industry Rotation Mixed A (011201) and GF Healthcare Stock A (004851), holding 1.2392 million shares and 959,000 shares respectively [3].

Group 1 - The core point of the article is that as of January 9, 2026, the total number of shareholders for the company is 7,406 [1]

Core Viewpoint - Shanghai Gaochong Technology Development Co., Ltd. has been established with a registered capital of 10 million RMB, fully owned by Jiangsu Jibeier Pharmaceutical Co., Ltd. [1] Group 1: Company Information - The legal representative of Shanghai Gaochong Technology Development Co., Ltd. is Liu Binghai [1] - The company is classified as a limited liability company with a business scope that includes technology services, development, consulting, and sales of specialized chemical products [1] - The registered address of the company is located at 668 Shangda Road, Building 1, 5th Floor, Area B, Baoshan District, Shanghai [1] Group 2: Shareholding Structure - Jiangsu Jibeier Pharmaceutical Co., Ltd. holds 100% of the shares in Shanghai Gaochong Technology Development Co., Ltd. [1] Group 3: Business Operations - The business operations include medical research and experimental development, marketing planning, conference and exhibition services, ticketing agency services, business secretary services, and technology intermediary services [1] - The company is authorized to conduct business activities independently based on its business license, except for projects that require approval by law [1] Group 4: Registration and Duration - The business registration is valid until January 8, 2026, with no fixed term thereafter [1] - The registration authority is the Baoshan District Market Supervision Administration [1]

Group 1 - The company is currently preparing for the production approval application of the antidepressant drug JJH201501 [2] - The company stated that it will accelerate the application process in accordance with relevant requirements [2] - Investors are encouraged to pay attention to the company's future disclosures regarding the progress of the application [2]